Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (22528)	6/19/1998 11:21:00 AM
From: rocket	Read Replies (1) \| Respond to of 32384

I agree biotechs have been out of favor and we've all seen our investments perform poorly in this sector for some years now. However, I remain convinced that good science will ultimately win out. Check out APHT today. Similar to LGND, it has excellent science, and is just now being discovered after years of working on strategic alliances, making progress through clinical trials, etc. The patient investor in LGND will someday be amply rewarded because the underlying science is remarkable. So, ignore the day to day machinations of the market and stick to your convictions. Karl

To: JOEBT1 who wrote (22528)	6/19/1998 12:47:00 PM
From: Andreas Helke	Respond to of 32384

I think the major danger for Ligand is that EntreMed or some other company is too successful with the development of a revolutionary new cancer treatment. That would make Ligands cancer franchise much less valuable than it is now. I think that even in that case Ligand could still be a successful company with its androgen program and the pharma collaborations in metabolic diseases osteoporosis heart disease and cytokines. When the angiogenesis news did heat up I decided to decrease Ligand from 30% to below 20% of my portfolio. But I am still waiting for the right selling price which went down from $35 to $20 to $15-$18 while the Ligand stock price continued to disappoint. Andreas